%0 Journal Article
%T Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double
%A C-H Lin
%A H-Y Lane
%A P-K Chen
%A S-H Wang
%J Journal of Psychopharmacology
%@ 1461-7285
%D 2019
%R 10.1177/0269881119849815
%X Sodium benzoate, a D-amino acid oxidase (DAAO) inhibitor, improved cognitive function of early-phase Alzheimer¡¯s disease (AD) after 24-week treatment. This study examined benzoate treatment for behavioral and psychological symptoms of dementia (BPSD). In a double-blind, 6-week trial, 97 patients with BPSD were randomized to receive placebo or benzoate (mean dose: 622.0£¿mg/day). The primary outcomes were ADAS-cog and BEHAVE-AD. Two treatments showed similar safety and primary and secondary outcomes. Compared to antecedent 24-week, higher-dose treatment for early-phase AD, benzoate appeared ineffective in this 6-week trial. Longer-duration, higher-dose trials are warranted to clarify its efficacy for BPSD
%K Behavioral and psychological symptoms of dementia (BPSD)
%K N-methyl-D-aspartate
%K D-amino acid oxidase (DAAO) inhibitor
%K sodium benzoate
%U https://journals.sagepub.com/doi/full/10.1177/0269881119849815